Please note: In October and November 2010, the MHRA moved from its Market Towers address to a new location on Buckingham Palace Road. Please go to the contact us section of the website for updated contact details.
This document is in .pdf format and can be downloaded at the bottom of this page.
In this issue:
Drug safety advice
-
Hormone-replacement therapy: updated advice
-
Tibolone: benefit-risk balance
-
Desmopressin nasal spray: removal of nocturnal enuresis indication
-
Pabrinex: allergic reactions
-
Corticosteroids: early psychiatric side-effects
Yellow Card scheme update
-
What to report
Hot topic
-
Duloxetine: marketed as Cymbalta and Yentreve for different disorders
Stop press
-
Recent letters to healthcare professionals
-
Latest safety information
Other information from the MHRA
-
New publication
-
Inspections
-
Advertising
Drug Safety Update: Volume 1, Issue 2, September 2007 
